Your session is about to expire
← Back to Search
CYAD-101 + Chemotherapy and Immunotherapy for Colorectal Cancer
Study Summary
This trial is testing a new cancer drug, CYAD-101, given with standard chemotherapy and immunotherapy drugs, to see if it is safe and works well against colorectal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor does not have high microsatellite instability.My cancer is a type of colon or rectal cancer that has spread.I have been treated with specific immune therapy drugs before.I have mild or no nerve damage from past chemotherapy.I have or had lung inflammation that needed steroids, confirmed by recent chest imaging.I have not had radiotherapy in the last 2 weeks.I am scheduled to receive FOLFOX chemotherapy.I haven't taken Filgrastim or similar drugs in the last 7 days.I have not received a live vaccine in the last 30 days.I have not had major surgery in the last 4 weeks.I do not have any serious illnesses that are not under control.My cancer in the colon or rectum cannot be removed by surgery.I am fully active or can carry out light work.I haven't taken any cancer drugs in the last 4 weeks.My cancer came back or got worse after treatment including FOLFOX.My heart, liver, kidneys, and lungs are working well.
- Group 1: CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide an overview of the previous studies conducted on CYAD-101?
"The first examination of CYAD-101 occurred in 2010 at City of Hope, with approximately 267 trials completed since that point. Currently, 961 clinical studies are actively recruiting participants; a high concentration is located around Jacksonville, Florida."
Has CYAD-101 gained clearance from the Federal Drug Administration?
"Taking into account that CYAD-101 is currently undergoing its initial trials, with limited data verifying safety and efficacy, our team at Power has issued a score of 1 for this drug's security."
Is enrollment for this research project still available?
"Affirmative. According to information available on clinicaltrials.gov, this research study is actively seeking participants from its initial posting date of November 22nd 2021 and was last edited February 22nd 2022. A total of 34 volunteers need to be selected across 3 sites for the trial's completion."
What therapeutic indications is CYAD-101 typically employed for?
"CYAD-101 is used to battle multiple malignant neoplasms and can be leveraged in cases of unresectable melanoma, microsatellite instability high tumours, or relapse after chemotherapy."
What is the total sample size for this clinical investigation?
"Affirmative. Clinicaltrials.gov suggests that this project, first put up on November 22nd 2021, is actively recruiting candidates. To complete the trial, 34 participants need to be enrolled at three different sites."
Share this study with friends
Copy Link
Messenger